GCTK
Glucotrack, Inc.
Next earnings ≈ Aug 12, 2026 · est. from filing cadence
Last earnings -4.3% on 2026-05-14
$0.33
▼ -0.30%$0.33▼ -94.71%
over 1Y
L $0.33EODHDH $10.59
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.3%
1W-9.3%
1M-48.2%
3M-66.7%
YTD-91.5%
1Y-94.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Revenue grew 378.3% YoY; but unprofitable (net margin -9321.2%).
Revenue (FY2019) $208K · FY2019
The read
Middling fundamentals offset by an attractive price (~335586% below fair value) — worth a look on the value angle.
Glucotrack, Inc. shows $208K in FY2019 revenue (+378.3% YoY), a -9321.2% net margin, and -685.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.04M | -$4.43M | -$7.10M | -$14.5M | -$16.1M |
| Net income | -$4.07M | -$4.43M | -$7.10M | -$22.6M | -$19.4M |
| Diluted EPS | $0.26 | $0.29 | $34.18 | $4,106.00 | $31.22 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$6.74M
EV / EBITDA—
EV / Sales-32.4
EV / FCF—
P / FCF—
PEG (trailing)0.00
Earnings yield-3021.8%
FCF yield-2390.2%
Quality & risk
ROIC (est.)-449.5%
Free cash flow-$15.3M
Total debt—
Net cash$7.38M
Altman Z-Score-33.35 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-92.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-05-15). Worth a closer look.
Recent filings
all on EDGAR ↗PRE 14APeriod ending 2026-06-172026-06-17open ↗8-KPeriod ending 2026-05-152026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗8-KPeriod ending 2026-05-072026-05-07open ↗EFFECTFiling2026-04-30open ↗8-KPeriod ending 2026-04-292026-04-30open ↗8-KPeriod ending 2026-04-302026-04-30open ↗POS AMFiling2026-04-29open ↗8-KPeriod ending 2026-04-142026-04-14open ↗10-KPeriod ending 2025-12-312026-03-30open ↗
Frequently asked
- Is Glucotrack, Inc. (GCTK) a buy?
- GCTK currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 378.3% YoY; but unprofitable (net margin -9321.2%).
- What is GCTK's fair value?
- A Modified-Graham model based on GCTK's SEC fundamentals estimates a fair value of about $1,107.76. It is an estimate from reported earnings, not a price target.
- Is GCTK overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, GCTK currently appears undervalued relative to its SEC-grounded earnings power.
- What is Glucotrack, Inc.'s quality score?
- GCTK scores 59.15686274509804/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001506983, latest 10-Q filed 2026-05-14) · EODHD · as of 6/22/2026, 9:54:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.